Safeya Maghraby, A. Ibrahim, Iman Montasser, Zeinab M. Hefny, M. Abdelwahed, Y. Massoud
{"title":"实时PCR和数字PCR检测埃及肝癌患者循环肿瘤DNA突变位点tp53 rs28934571的临床应用价值评价","authors":"Safeya Maghraby, A. Ibrahim, Iman Montasser, Zeinab M. Hefny, M. Abdelwahed, Y. Massoud","doi":"10.21608/jesp.2023.312105","DOIUrl":null,"url":null,"abstract":"Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is the fourth cause of cancer and the second -related mortality . The P53 is considered the guardian of the genome to prevent accumulation of oncogenic mutations that lead to malignant tumor. The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation gene locus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and in hepatocellular carcinoma ( HCC) ones to evaluate its diagnostic value and analyses the ctDNA by targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T). The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC on top of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matched as to age and sex. The AST was increased in HCC patients as compared to healthy con-trol ( P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) within USCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with mean score of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions, eight patients had four focal lesions and six patients had multiple lesions. The average size of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developed ascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy . There was no significant difference in genetic typing between HCC patients, HCV ones and healthy controls (p =0.622) .","PeriodicalId":17289,"journal":{"name":"Journal of the Egyptian Society of Parasitology","volume":"2016 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS\",\"authors\":\"Safeya Maghraby, A. Ibrahim, Iman Montasser, Zeinab M. Hefny, M. Abdelwahed, Y. Massoud\",\"doi\":\"10.21608/jesp.2023.312105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is the fourth cause of cancer and the second -related mortality . The P53 is considered the guardian of the genome to prevent accumulation of oncogenic mutations that lead to malignant tumor. The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation gene locus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and in hepatocellular carcinoma ( HCC) ones to evaluate its diagnostic value and analyses the ctDNA by targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T). The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC on top of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matched as to age and sex. The AST was increased in HCC patients as compared to healthy con-trol ( P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) within USCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with mean score of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions, eight patients had four focal lesions and six patients had multiple lesions. The average size of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developed ascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy . There was no significant difference in genetic typing between HCC patients, HCV ones and healthy controls (p =0.622) .\",\"PeriodicalId\":17289,\"journal\":{\"name\":\"Journal of the Egyptian Society of Parasitology\",\"volume\":\"2016 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Egyptian Society of Parasitology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/jesp.2023.312105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian Society of Parasitology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/jesp.2023.312105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS
Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is the fourth cause of cancer and the second -related mortality . The P53 is considered the guardian of the genome to prevent accumulation of oncogenic mutations that lead to malignant tumor. The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation gene locus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and in hepatocellular carcinoma ( HCC) ones to evaluate its diagnostic value and analyses the ctDNA by targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T). The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC on top of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matched as to age and sex. The AST was increased in HCC patients as compared to healthy con-trol ( P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) within USCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with mean score of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions, eight patients had four focal lesions and six patients had multiple lesions. The average size of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developed ascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy . There was no significant difference in genetic typing between HCC patients, HCV ones and healthy controls (p =0.622) .